As the demand for affordable healthcare options grows, the pharmaceutical industry is increasingly focused on developing generic drugs to expand access and reduce costs. This trend is driving major players to seek FDA approvals for generic versions of popular medications, reshaping the competitive landscape and providing more choices for consumers.
Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), announced the FDA approval and U.S. launch of a generic version of Novo Nordisk A/S' (NYSE:NVO) Saxenda (liraglutide injection).
